600267 Zhejiang Hisun Pharmaceutical
- 7.80
- +0.03+0.39%
Zhejiang Hisun Pharmaceutical News
Announcement from Zhejiang Hisun Pharmaceutical Co., Ltd. regarding the approval of the listing application of Epobispar Emine Active Pharmaceutical Ingredient in the 'Notification of Approval of Chemical Raw Materials for Market Application'
Zhejiang Hisun Pharmaceutical: Announcement of the first release of the restricted stock incentive plan for 2021 and the second release of the lifting of the sales restriction period and the listing of stocks of Zhejiang Hisun Pharmaceutical Co., Ltd.
Zhejiang Hisun Pharmaceutical: Announcement of the subsidiary of Zhejiang Hisun Pharmaceutical Co., Ltd. obtaining the approval number for veterinary drug products.
Announcement of the resolution of the 16th meeting of the ninth supervisory committee of Zhejiang Hisun Pharmaceutical Co., Ltd.
Legal Opinion on the Removal of Restrictions on Zhejiang Hisun Pharmaceutical Co., Ltd.'s Restricted Stock Incentive Plan for 2021 by Shanghai Junlan Law Firm.
Announcement on the first release of the 2021 Restricted Stock Incentive Plan and the achievement of the second release restriction on Zhejiang Hisun Pharmaceutical Co., Ltd.
Announcement of the resolution of the 29th meeting of the 9th Board of Directors of Zhejiang Hisun Pharmaceutical Co., Ltd.
Announcement of Zhejiang Hisun Pharmaceutical Co., Ltd. on the Consistency Evaluation of Its Pharmaceutical Products with Generic Drugs
Announcement of Subsidiary of Zhejiang Hisun Pharmaceutical Co., Ltd. Obtaining New Veterinary Drug Registration Certificate.
Announcement from Zhejiang Hisun Pharmaceutical Co., Ltd. regarding its wholly-owned subsidiary obtaining approval for listing application of Efavirenz as an active pharmaceutical ingredient in the Chemical Raw Materials category.
Announcement of Subsidiary of Zhejiang Hisun Pharmaceutical Co., Ltd. Obtaining New Veterinary Drug Registration Certificate.
Announcement of subsidiary pharmaceuticals passing the generic consistency evaluation by Zhejiang Hisun Pharmaceutical Co., Ltd.
Announcement of Zhejiang Hisun Pharmaceutical Co., Ltd. on its subsidiary obtaining a pharmaceutical registration certificate.
Tianjian Certified Public Accountants LLP's special general partnership explanatory statement on the information disclosure supervision work letter regarding Zhejiang Hisun Pharmaceutical Co., Ltd.'s 2023 Annual Report.
Zhejiang Hisun Pharmaceutical Co., Ltd.'s announcement in response to the Shanghai Stock Exchange's regulatory work letter regarding the company's 2023 annual report information disclosure.
Announcement of the resolution of the 28th meeting of the 9th board of directors of Zhejiang Hisun Pharmaceutical Co., Ltd.
Announcement of subsidiary pharmaceuticals passing the generic consistency evaluation by Zhejiang Hisun Pharmaceutical Co., Ltd.
Announcement of zhejiang hisun pharmaceutical co., LTD. about its subsidiary receiving government subsidies.
Announcement of Subsidiary of Zhejiang Hisun Pharmaceutical Co., Ltd. Obtaining New Veterinary Drug Registration Certificate.
Announcement of Zhejiang Haizheng Pharmaceutical Co., Ltd. on the delisting of “Haizheng Dingzhan” convertible bonds
Analysis
Price Target
No Data
